Evidence map›Paper›PMID 38768235›Full record

ArticlePLoS pathogens2024

Quantifying the fitness effects of resistance alleles with and without anthelmintic selection pressure using Caenorhabditis elegans.

Amanda O Shaver, Isabella R Miller, Etta S Schaye, Nicolas D Moya, J B Collins, Janneke Wit, Alyssa H Blanco, Fiona M Shao, Elliot J Andersen, Sharik A Khan and 2 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Veterinarni medicina · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Quantitative tests of albendazole resistance in beta-tubulin mutants.bioRxiv : the preprint server for biology · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Amanda O ShaverMolecular Biosciences, Northwestern University, Evanston, Illinois, United States of America.ORCID 0000-0002-2910-1505
Isabella R MillerMolecular Biosciences, Northwestern University, Evanston, Illinois, United States of America.
Etta S SchayeMolecular Biosciences, Northwestern University, Evanston, Illinois, United States of America.
Nicolas D MoyaDept. of Biology, Johns Hopkins University, Baltimore, Maryland, United States of America.
J B CollinsMolecular Biosciences, Northwestern University, Evanston, Illinois, United States of America.
Janneke WitMolecular Biosciences, Northwestern University, Evanston, Illinois, United States of America.
Alyssa H BlancoMolecular Biosciences, Northwestern University, Evanston, Illinois, United States of America.
Fiona M ShaoMolecular Biosciences, Northwestern University, Evanston, Illinois, United States of America.
Elliot J AndersenMolecular Biosciences, Northwestern University, Evanston, Illinois, United States of America.
Sharik A KhanMolecular Biosciences, Northwestern University, Evanston, Illinois, United States of America.
Gracie ParedesMolecular Biosciences, Northwestern University, Evanston, Illinois, United States of America.
Erik C AndersenDept. of Biology, Johns Hopkins University, Baltimore, Maryland, United States of America.ORCID 0000-0003-0229-9651

Funding

Discovery of Novel Benzimidazole Resistance MechanismsR01AI153088 · NIAID · NORTHWESTERN UNIVERSITY · PI Erik Christian Andersen, James Solomon Fraser · 2020 to 2026
$4.3M
NIAID NIH HHS R01 AI153088
6 · The paper itself

Abstract

Albendazole (a benzimidazole) and ivermectin (a macrocyclic lactone) are the two most commonly co-administered anthelmintic drugs in mass-drug administration programs worldwide. Despite emerging resistance, we do not fully understand the mechanisms of resistance to these drugs nor the consequences of delivering them in combination. Albendazole resistance has primarily been attributed to variation in the drug target, a beta-tubulin gene. Ivermectin targets glutamate-gated chloride channels (GluCls), but it is unknown whether GluCl genes are involved in ivermectin resistance in nature. Using Caenorhabditis elegans, we defined the fitness costs associated with loss of the drug target genes singly or in combinations of the genes that encode GluCl subunits. We quantified the loss-of-function effects on three traits: (i) multi-generational competitive fitness, (ii) fecundity, and (iii) development. In competitive fitness and development assays, we found that a deletion of the beta-tubulin gene ben-1 conferred albendazole resistance, but ivermectin resistance required the loss of two GluCl genes (avr-14 and avr-15). The fecundity assays revealed that loss of ben-1 did not provide any fitness benefit in albendazole conditions and that no GluCl deletion mutants were resistant to ivermectin. Next, we searched for evidence of multi-drug resistance across the three traits. Loss of ben-1 did not confer resistance to ivermectin, nor did loss of any single GluCl subunit or combination confer resistance to albendazole. Finally, we assessed the development of 124 C. elegans wild strains across six benzimidazoles and seven macrocyclic lactones to identify evidence of multi-drug resistance between the two drug classes and found a strong phenotypic correlation within a drug class but not across drug classes. Because each gene affects various aspects of nematode physiology, these results suggest that it is necessary to assess multiple fitness traits to evaluate how each gene contributes to anthelmintic resistance.

Indexed as

AnthelminticsCaenorhabditis elegansDrug ResistanceIvermectinAlbendazoleAllelesAnimalsCaenorhabditis elegans ProteinsChloride ChannelsGenetic FitnessSelection, GeneticTubulinAlbendazoleAnthelminticsCaenorhabditis elegans ProteinsChloride Channelsglutamate-gated chloride channelsIvermectinTubulin

Identifiers

PMID38768235
PMCPMC11142691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.